| Literature DB >> 30076721 |
Youqiang Sun1,2,3, Vincent Kuek2, Yuhao Liu1,2,3, Jennifer Tickner2, Yu Yuan4, Leilei Chen1,3, Zhikui Zeng1,3, Min Shao3,5, Wei He1,3, Jiake Xu2,3.
Abstract
MiR-214 belongs to a family of microRNA (small, highly conserved noncoding RNA molecules) precursors that play a pivotal role in biological functions, such as cellular function, tissue development, tissue homeostasis, and pathogenesis of diseases. Recently, miR-214 emerged as a critical regulator of musculoskeletal metabolism. Specifically, miR-214 can mediate skeletal muscle myogenesis and vascular smooth muscle cell proliferation, migration, and differentiation. MiR-214 also modulates osteoblast function by targeting specific molecular pathways and the expression of various osteoblast-related genes; promotes osteoclast activity by targeting phosphatase and tensin homolog (Pten); and mediates osteoclast-osteoblast intercellular crosstalk via an exosomal miRNA paracrine mechanism. Importantly, dysregulation in miR-214 expression is associated with pathological bone conditions such as osteoporosis, osteosarcoma, multiple myeloma, and osteolytic bone metastasis of breast cancer. This review discusses the cellular targets of miR-214 in bone, the molecular mechanisms governing the activities of miR-214 in the musculoskeletal system, and the putative role of miR-214 in skeletal diseases. Understanding the biology of miR-214 could potentially lead to the development of miR-214 as a possible biomarker and a therapeutic target for musculoskeletal diseases.Entities:
Keywords: breast cancer; miR-214; multiple myeloma (MM); muscle; osteoblast; osteoclast; osteoporosis; osteosarcoma (OS)
Mesh:
Substances:
Year: 2018 PMID: 30076721 DOI: 10.1002/jcp.26856
Source DB: PubMed Journal: J Cell Physiol ISSN: 0021-9541 Impact factor: 6.384